Patients with HER2-positive early breast cancer (EBC) preferred subcutaneous (SC) trastuzumab, delivered via single-use injection device (SID), over the intravenous (IV) formulation (Cohort 1 of the PrefHer study: NCT01401166). Here we report patient preference, healthcare professional satisfaction, and safety data pooled from Cohort 1 and also Cohort 2, where SC trastuzumab was delivered via hand-held syringe.
Conclusion
PrefHer revealed compelling and consistent patient preferences for SC over IV trastuzumab, regardless of SID or hand-held syringe delivery. SC was well tolerated and safety was consistent with previous reports, including the HannaH study (NCT00950300). No new safety signals were identified compared to the known IV profile in EBC. PrefHer and HannaH confirm that SC trastuzumab is a validated and preferred option over IV for improving patients' care in HER2-positive breast cancer.
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INTRODUCTION
Trastuzumab-containing regimens are standard of care for HER2-positive early breast cancer (EBC) and metastatic breast cancer (MBC) [1] [2] [3] . A 600 mg fixed-dose manual injection of subcutaneous trastuzumab (Herceptin ® SC, F. Hoffmann-La Roche Ltd, Basel, Switzerland) given via hand-held syringe is approved by the European Medicines Agency for EBC and MBC as an alternative to conventional intravenous (IV) infusion, based on results of the phase III HannaH study (NCT00950300) [4, 5] . An SC single-use injection device (SID) has comparable pharmacokinetics and safety to the hand-held syringe [6] .
Intuitively, SC trastuzumab should be more convenient for patients as administration requires only 2-5 minutes [7] . Objectively, reductions in patients' infusion chair time, healthcare professionals' time, and other hospital resources have been demonstrated [8, 9] . The international, open-label, randomized, PrefHer study (NCT01401166) examined patients' preferences in the adjuvant breast cancer setting for IV or SC delivery via two cohorts using both methods of SC trastuzumab administration (SID or hand-held syringe) [10] . We present additional and final results of patient preferences in the overall study population (data pooled from both cohorts).
METHODS
Patients
Patient eligibility criteria have been described previously [10] and are available in the supplementary material, available at Annals of Oncology online.
Study Design
After surgery and completion of (neo)adjuvant chemotherapy, patients were randomized to receive 4 adjuvant cycles of SC trastuzumab (600 mg fixed dose injected into the thigh over approximately 5 minutes) every 3 weeks followed by 4 cycles of IV (8 mg/kg loading dose if the patient was randomized to receive IV trastuzumab first, 6 mg/kg maintenance doses) every 3 weeks or vice-versa (the crossover period, which was assessed in this report) as part of their standard trastuzumab [10] . Stratification was by de novo and non-de novo trastuzumab groups. Patients received SC trastuzumab via the SID in Cohort 1 and the hand-held syringe in Cohort 2. Following the crossover period patients received IV trastuzumab in Cohort 1 (unless participating in SID self-administration) and SC trastuzumab via hand-held syringe in Cohort 2. The primary endpoint was the proportion of patients indicating an overall preference for SC or IV in each cohort, assessed by two study-specific telephone patient interviews (PINTs): one before randomization and one after the crossover period. PINTs were conducted by experienced telephone interviewers and were stringently quality-controlled to ensure impartial questioning. The first interview (PINT1) probed factors that could potentially influence preferences, such as previous experiences with drug delivery methods, needle phobias, and expected preferences for SC or IV trastuzumab. The second interview (PINT2) probed patients' experiences with each administration method on-study, final preference, strength of the preference and reasons for it. Factors influencing preference, strength of the preference, and reasons for it were exploratory endpoints. Patients in the SID cohort with ≥2 cycles remaining after crossover had the option to selfadminister the SID, with their satisfaction assessed by questionnaire after first and last self-administrations as an exploratory endpoint. Secondary endpoints were safety and tolerability (assessed using standard methods [11-13]), event-free survival, immunogenicity (anti-trastuzumab and anti-recombinant human hyaluronidase [rHuPH20] antibodies in blood samples, taken at baseline and pre-dose cycle 5, i.e. before crossover) in the SID cohort only, healthcare professional satisfaction (assessed by responses of gynecologists, oncologists, oncology/specialist chemotherapy nurses, other healthcare professionals to the questionnaire question "All things considered with which method of administration were you most satisfied?" after the crossover period), and healthcare professional-perceived time savings with SC trastuzumab, also assessed by questionnaire.
PrefHer was conducted in accordance with Good Clinical Practice guidelines and the Declaration of Helsinki. All participating patients provided written informed consent. Approval for the protocol was obtained from appropriate local and national independent ethics committees.
Statistical Analyses
Preference for SC was compared in a non-protocol-specified analysis with a two-sided test against a null hypothesis value of 65% [10]. Each cohort was powered independently. Factors potentially influencing preference were assessed in terms of their effect on the primary endpoint using logistic regression (forward selection by stepwise regression with alpha 0.05) in an exploratory manner.
Statistical analyses were performed with SAS (version 9.1.3).
Adverse event (AE) analyses are descriptive only.
RESULTS
Patients
From October 27, 2011 to December 3, 2012, 488 patients were randomized ( Figure 1 ). The safety population included 483 patients (five randomized patients did not receive study treatment): 243 SC→IV and 240 IV→SC. Baseline patient demographics, tumor characteristics, and treatment history were balanced between study arms (Table 1) .
Patient Preference
Primary Endpoint
At PINT2, 88.9% of patients (415/467) preferred SC (95% CI, 85.7-91.6; P < 0.0001, two-sided test against the null hypothesis of 65% SC preference), 9.6% (45/467, 95% CI, 7.1-12.7) preferred IV, and 1.5% (7/467, 95% CI, 0.6-3.1) had no preference ( Figure 2 ). Results were consistent in both study arms: 
Exploratory Analysis: Strength of Preferences
Overall preference for SC was "very strong" in 64.9% of patients (303/467; 95% CI, 60.4-69.2), "fairly strong" in 17.3% (81/467, 95% CI, 14.0-21.1), and "not very strong" in 6.6% (31/467, 95% CI, 4.6-9.3). Overall preference for IV was "very strong" in 5.1% of patients (24/467, 95% CI, 3.3-7.6), "fairly strong" in 2.1% (10/467, 95% CI, 1.0-3.9), and "not very strong" in 2.4% (11/467, 95% CI, 1.2-4.2).
Exploratory Analysis: Reasons for Patients' Preferences
The two main reasons that patients gave for preferring SC were that it saved time and that it resulted in less pain/discomfort/side effects ( 
Predefined Exploratory Endpoint: Factors Influencing Preference
There was a high preference by patients for SC trastuzumab regardless of whether they had received IV trastuzumab before enrollment ( Figure 2 ). Four terms were found to be significant and therefore kept in the final stepwise logistic regression model to select factors that potentially influence preference ( Supplementary Table S1 ): expected preferences given at PINT1 (odds ratio [OR] 2.98, 95% CI, 1.51-5.88), weight (OR 0.41, 95% CI, 0.17-0.97), needle phobia/anxiety (OR 0.31, 95% CI, 0.14-0.68), and IV delivery type for prior chemotherapy (OR 2.31, 95% CI, 1.21-4.41). However, these results should be interpreted with caution due to the low number of patients who expressed a preference for IV or expressed no preference.
Hypothetical preference from PINT1 was a factor that influenced final preferences. Of the patients who expressed a prior preference for SC, 94.0% (203/216) expressed a final preference for SC ( Table S2 ). Table   S3 ).
Exploratory Analysis: Hypothetical Preferred Location and Route of
Secondary Endpoint: Healthcare Professional Satisfaction
Two hundred thirty-five healthcare professional questionnaires were completed. Responses indicated that most respondents were more satisfied with SC administration (77.0% [181/235], 95% CI, 71.1-82.2) than with IV (3.0% [7/235], 95% CI, 1.2-6.0). The remaining 20.0% [47/235], 95% CI, 15.1-25.7) indicated no preference for either route.
Secondary Endpoint: AE Profile
The AE profile obtained during the crossover period at this interim safety analysis is shown in Table 4 . Differences between rates in the pooled SC and IV periods were driven by grade 1 events occurring more frequently during the SC period. Influenza, dermatitis, syncope, hypertension, left ventricular dysfunction, and dyspnea were the most common grade 3 AEs (0.4% of patients [two] each). No patients had a grade 4 or 5 AE. No serious AEs were considered to be related to trastuzumab and each was resolved without sequelae. Twenty-four of 483 patients experienced cardiac events, but only two instances were recorded as grade 3 (both were left ventricular dysfunction). No cardiac events were reported as serious and there was one case of congestive heart failure (grade 2; resolved without sequelae).
Secondary Endpoint: Immunogenicity
In the SC→IV and IV→SC arms, anti-trastuzumab antibody rates were 0% (0/114 evaluable patients [any patient with a pre-dose cycle 5 trastuzumab or rHuPH20 antibody result regardless of baseline result]) and 3.4% (4/119), respectively, and the anti-rHuPH20 antibody rates were 2.6% (3/115) and 7.6% (9/119), respectively. No association between AEs and the presence of anti-trastuzumab or -rHuPH20 antibodies was observed (data not shown).
DISCUSSION
Final preference results from PrefHer showed that patients strongly preferred SC trastuzumab, regardless of SID or hand-held syringe delivery. These data Interpretation of safety analyses should also take into account the limitations of having a short period of time during which the events were recorded for this analysis (eight 3-weekly cycles). Future analyses will assess data from the continuation periods once all patients have completed follow-up.
The apparent discrepancy between increased clinician-reported AEs during the SC period and patients' reports of SC producing less pain, bruising, and irritation may have resulted from a more conservative approach to reporting due to inexperience with the SC formulation [4] .
Healthcare professionals were more satisfied with SC regardless of administration method. The time-and-motion sub-study has shown that healthcare professional time and center costs may be substantially reduced using the SID or the hand-held syringe [8, 9] , and that healthcare professional-perceived clinical management and efficiency was increased with either SC method, to the benefit of different stakeholders [9, 18] . Combined with the totality of the clinical and patient preference data, SC trastuzumab has been shown to provide benefits to both patients and healthcare systems.
In conclusion, PrefHer revealed compelling and consistent patient preference for SC trastuzumab, regardless of delivery method (SID or hand-held syringe).
Healthcare professionals were also more satisfied with SC over IV administration and SC was well tolerated. Safety data, including immunogenicity, were consistent with previous reports and no new safety signals were identified compared to the known IV profile in EBC.
Based on data from HannaH and PrefHer, SC trastuzumab is the validated and preferred option over IV for improving patients' care in HER2-positive breast cancer.
KEY MESSAGE
PrefHer revealed compelling and consistent patient preference for subcutaneous (SC) trastuzumab, regardless of delivery by single-use injection device or hand-held syringe. SC trastuzumab was well tolerated and safety data, including immunogenicity data, were consistent with previous reports.
No new safety signals were identified compared to the known intravenous trastuzumab profile in early breast cancer.
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ECOG, Eastern Cooperative Oncology Group; HER2, human epidermal growth factor receptor 2; IV, intravenous; SC, subcutaneous; SD. Responses to the question "What are the two main reasons for your preference?" were recorded verbatim by the interviewer. Patients could be counted in both the SC and IV period columns. Responses to the question "All things considered, which method of administration did you prefer?"
Error bars represent 95% confidence intervals. IV, intravenous; SC, subcutaneous. Supplementary Table S1 . Logistic Regression (Evaluable Intention-to-Treat
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Terms not kept in the final logistic regression were: study arm (SC→IV vs IV→ SC), prestudy trastuzumab treatment, country, age (<60 vs 60 years), difficulty traveling to chemotherapy appointments (yes vs no), and IV delivery type for prior trastuzumab at PINT2. CI, confidence interval; IV, intravenous; PINT, Patient interview; SC, subcutaneous.
Supplementary Table S2. Patient Preference by Country (Evaluable
Intention-to-Treat Population) CI, confidence interval; IV, intravenous; SC, subcutaneous.
Supplementary Table S3. Hypothetical Preferred Location and Route of Trastuzumab Administration (Evaluable Intention-to-Treat Population)
Responses to the question "So if you could choose IV or SC given at: cancer center or clinic, your local hospital, your GP or primary care physician's office, Responses to the question "All things considered, which method of administration did you prefer?"
Error bars represent 95% confidence intervals.
IV, intravenous; SC, subcutaneous. 
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